EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 15-Dec-2025 08:11 ET (15-Dec-2025 13:11 GMT/UTC)

7-Dec-2025

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

American Society of Hematology
Reports and Proceedings

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

7-Dec-2025

New findings support a chemo-free approach for treating Ph+ ALL

American Society of Hematology
Reports and Proceedings

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

University of Cincinnati experts present research at annual hematology event

University of Cincinnati
Meeting Announcement

University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6-9 in Orlando.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

6-Dec-2025

ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data from researchers at The University of Texas MD Anderson Cancer Center.

6-Dec-2025

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

University of Miami Miller School of Medicine
Reports and Proceedings

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center. The findings will be presented Dec. 6, 2025, at the American Society of Hematology (ASH) annual meeting in Orlando.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

University of Miami Miller School of Medicine
Reports and Proceedings

EMBARGOED: A new study to be presented Dec. 6 at the 2025 American Society of Hematology (ASH) meeting reveals that even subtle disruptions in genome architecture can predispose individuals to lymphoma. This finding offers a new perspective on understanding and eventually treating blood cancers.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

American Society of Hematology
Reports and Proceedings

A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure safe and effective even when donors and recipients are unrelated and have extensive genetic mismatches.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Continuous and fixed-duration treatments result in similar outcomes for CLL

American Society of Hematology
Reports and Proceedings

According to a new trial, patients with chronic lymphocytic leukemia show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

American Society of Hematology
Reports and Proceedings

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients with acute myeloid leukemia (AML), according to a new study from the HARMONY Alliance.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition